Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2014 Mar;53(3):227-45. doi: 10.1007/s40262-013-0124-z. Review.

PMID:
24327238
2.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2007;46(1):13-58. Review.

PMID:
17201457
3.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Abd Rahman AN, Tett SE, Staatz CE.

Clin Pharmacokinet. 2013 May;52(5):303-31. doi: 10.1007/s40262-013-0039-8. Review.

PMID:
23475567
4.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.

PMID:
21190834
5.

Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?

Staatz CE, Tett SE.

Clin Pharmacokinet. 2011 Dec 1;50(12):759-72. doi: 10.2165/11596380-000000000-00000. Review.

PMID:
22087863
6.

Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.

Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.

PMID:
19817503
7.

Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.

de Winter BC, van Gelder T, Mathot RA, Glander P, Tedesco-Silva H, Hilbrands L, Budde K, van Hest RM.

Ther Drug Monit. 2009 Oct;31(5):585-91. doi: 10.1097/FTD.0b013e3181b8679a.

PMID:
19704401
8.

Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.

Pawinski T, Luszczynska P, Durlik M, Majchrzak J, Baczkowska T, Chrzanowska M, Sobiak J, Glyda M, Kuriata-Kordek M, Kamińska D, Krajewska M, Klinger M.

Ther Drug Monit. 2013 Dec;35(6):760-9. doi: 10.1097/FTD.0b013e31829b88f5.

PMID:
24192641
9.

Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease.

de Winter BC, Neumann I, van Hest RM, van Gelder T, Mathot RA.

Ther Drug Monit. 2009 Jun;31(3):382-90. doi: 10.1097/FTD.0b013e3181a23f1a.

PMID:
19363460
10.

Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.

Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, Sabbatini M.

Nephrol Dial Transplant. 2011 Sep;26(9):3019-25. doi: 10.1093/ndt/gfq819. Epub 2011 Feb 11.

11.

Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.

Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P.

Clin Pharmacokinet. 2008;47(4):277-84.

PMID:
18336056
13.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
14.

Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients.

Li J, Liu Y, Huang J, Fu Q, Chen E, Liu L, Zhang R, Huang M, Wang C.

Am J Nephrol. 2013;37(6):534-40. doi: 10.1159/000351180. Epub 2013 May 15.

PMID:
23689735
15.

Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.

de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA.

Clin Pharmacokinet. 2008;47(12):827-38. doi: 10.2165/0003088-200847120-00007.

PMID:
19026038
16.

[Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients].

Yang SL, Gao X, Wang QH, Zhang J, Cai JQ, Guo JQ, Tang MY, Shang LL, Tan JM.

Zhonghua Yi Xue Za Zhi. 2013 Dec 24;93(48):3841-6. Chinese.

PMID:
24548445
17.

Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.

Yin H, Qiu K, Hu XP, Li XB, Wang W, Liu LH, Zhang XD.

Int J Clin Pract Suppl. 2014 Apr;(181):31-7. doi: 10.1111/ijcp.12404.

PMID:
24673717
18.
20.
Items per page

Supplemental Content

Write to the Help Desk